Kiniksa Pharmaceuticals International, Plc(NASDAQ) KNSA

Kiniksa makes medicines for rare and painful heart conditions. Its main product helps reduce swelling around the heart. These treatments aim to improve life for sick patients.

Rare Disease Medicine Portfolio

• ARCALYST: An injection used to treat recurrent pericarditis, a painful condition involving heart inflammation.
• KPL-387: An experimental drug currently being tested as a monthly, at-home heart treatment.
• KPL-1161: A potential new therapy designed to last longer for less frequent dosing.
• Abiprubart: A drug candidate for autoimmune diseases that the company plans to sell.

How the Company Expands

• In April 2026, the FDA began reviewing a move to transfer drug manufacturing to Samsung Biologics.
• Kiniksa and Regeneron split profits equally on all commercial sales of the heart drug ARCALYST.
• The company partnered with Huadong in 2022 to sell heart treatments in Asia and Oceania.
• In 2022, the company licensed its drug candidate vixarelimab to Genentech for worldwide development.

What Makes the Business Different?

Kiniksa focuses entirely on heart and autoimmune diseases using immune-modulating technology. It manages these efforts as a single business segment to maintain operational efficiency.

Strong Results in Q1 2026

• Total revenue reached $214.3 million in Q1 2026, up 55.5% year-over-year.
• Net income hit $22.6 million in Q1 2026, up 164.6% from the previous year.
• Free cash flow grew to $50 million in Q1 2026, up 125.1% year-over-year.
• Total cash and short-term investments reached $468.1 million by March 31, 2026.

Bottom Line

Kiniksa has successfully moved from drug research to a profitable commercial stage. Its future depends on the performance of its lead heart drug and the success of its experimental pipeline.